What is dragon's blood resin used for medicinally?

Dragon's blood resin from Dracaena cinnabari is used traditionally in Yemeni and Socotran folk medicine primarily for wound healing, hemostasis, antidiarrheal treatment, and peptic ulcer relief. Preclinical research has additionally identified antioxidant (IC50 25.5 μg/mL), anti-inflammatory, antidiabetic, and anticancer activities in cell and rodent models, though none of these effects have been confirmed in human clinical trials.

Is Dracaena cinnabari dragon's blood safe to consume?

In rodent toxicity studies, methanolic resin extract was administered at up to 1500 mg/kg daily for 28 days without observed toxic effects, suggesting low acute toxicity in animals. However, no human safety studies exist, no safe human dose has been established, and potential interactions with anticoagulant or antidiabetic medications cannot be ruled out; consumption should be approached with caution and ideally under medical supervision.

What are the active compounds in dragon's blood resin?

The resin contains a diverse array of bioactive compounds including flavonoids such as 7,4′-dihydroxy-3′-methoxyflavan, homoisoflavonoids including 7,8-methylenedioxy-3(4-hydroxybenzyl)chromane, the anthocyanin-like pigment dracorhodin, chalcones, gallic acid, condensed tannins, sterols (lupeol, campesterol), and saponins. The homoisoflavonoids and dracorhodin are considered particularly characteristic of this species and drive much of its observed antioxidant and anti-inflammatory activity.

Are there any clinical trials on Dracaena cinnabari?

No human clinical trials on Dracaena cinnabari have been published in the available scientific literature. Evidence is limited to in vitro experiments demonstrating cytotoxicity against MCF-7 breast cancer cells (IC50 48–115 μg/mL) and rodent studies showing blood glucose reduction and reduced oral carcinoma incidence, all of which have methodological limitations including unreported sample sizes and absence of pharmacokinetic data.

What is the recommended dosage of dragon's blood resin supplement?

No standardized supplemental dose for Dracaena cinnabari resin has been established for humans, as no clinical trials have been conducted to define an effective or safe human dose. Preclinical rodent studies have used methanol or ethanolic extracts at 100–1000 mg/kg for biological effects and demonstrated tolerability up to 1500 mg/kg in 28-day rat studies, but these figures cannot be reliably converted to human doses without pharmacokinetic bridging studies.

Does dragon's blood resin interact with blood thinners or anticoagulant medications?

Dragon's blood resin possesses hemostatic properties due to its tannins and dracorhodin content, which may theoretically enhance clotting. Individuals taking anticoagulants (such as warfarin) or antiplatelet medications (such as aspirin) should consult a healthcare provider before supplementing, as the resin's procoagulant effects could potentially counteract these medications. Combined use requires medical supervision to monitor bleeding time and therapeutic efficacy.

What is the difference between dragon's blood resin extract and whole resin powder?

Dragon's blood resin extract is a concentrated form where solvents isolate the active compounds (tannins, phenolic acids, and dracorhodin), typically offering higher potency per dose than whole resin powder. Whole resin powder contains all plant constituents including inert material, requiring larger doses to achieve similar bioactive concentrations. Extracts generally provide faster absorption and more standardized active compound levels, making them preferable for therapeutic applications targeting wound healing and hemostasis.

Who should avoid dragon's blood resin supplementation?

Individuals with bleeding disorders, those taking anticoagulant or antiplatelet medications, and pregnant or nursing women should avoid dragon's blood resin due to its potent hemostatic effects and limited safety data in these populations. People with hypersensitivity to Dracaena species or related plant families may experience allergic reactions. Those scheduled for surgery should discontinue use at least 2 weeks prior due to potential interference with bleeding control during the procedure.

Dragon's Blood

Dracaena cinnabari resin contains a complex of flavonoids, homoisoflavonoids, dracorhodin, and chalcones that exert antioxidant, anti-inflammatory, hemostatic, and antidiabetic effects primarily through free radical scavenging, cytokine suppression, and enzyme inhibition. In preclinical models, the methanolic resin extract demonstrated α-glucosidase inhibition with an IC50 of 40.27 μg/mL and antioxidant activity with an IC50 of 25.5 μg/mL, while reducing oral squamous cell carcinoma incidence in mice at 1000 mg/kg.

Category: Middle Eastern Evidence: 1/10 Tier: Preliminary

Origin & History

Dracaena cinnabari is endemic to Socotra Island, Yemen, where it grows in the arid, rocky plateau environments of the Haghier Mountains at elevations between 300 and 1500 meters. The tree thrives in the semi-arid monsoon climate of the Arabian Sea archipelago, characterized by seasonal fog and well-drained limestone soils. Its iconic umbrella-shaped canopy and slow growth cycle have made it culturally and ecologically central to Socotra's landscape for millennia.

Historical & Cultural Context

Dragon's blood resin from Dracaena cinnabari has been harvested and traded from Socotra Island for at least two millennia, appearing in ancient Greek, Roman, and Arab trade records as a prized red pigment, varnish, and medicine. In Yemeni and Socotran folk medicine, the resin—locally known as 'Akhwain'—has been applied topically for wound healing, hemostasis, and skin infections, and ingested for diarrhea, peptic ulcers, and respiratory ailments. Within Ayurvedic traditions, dragon's blood resins (though often from related Dracaena and Daemonorops species) have been employed for similar indications under the name 'Rakta Skandha,' reflecting shared cross-cultural recognition of its bioactive properties. The tree's iconic silhouette has become a symbol of Socotra's unique biodiversity, and the resin remains in active traditional use despite the island's relative geographic isolation.

Health Benefits

- **Wound Healing and Hemostasis**: The resin's tannins, phenolic acids such as gallic acid, and dracorhodin pigment contribute to astringent and hemostatic properties traditionally used to arrest bleeding and accelerate wound closure in Yemeni folk medicine.
- **Antioxidant Protection**: The homoisoflavonoid 7,8-methylenedioxy-3(4-hydroxybenzyl)chromane demonstrates free radical scavenging activity comparable to quercetin, with a methanolic extract IC50 of 25.5 μg/mL, suggesting meaningful oxidative stress reduction.
- **Anti-inflammatory Activity**: Flavonoid-rich fractions inhibit nitrite production, TNF-α, and IL-6 secretion in LPS-stimulated RAW 264.7 macrophages, indicating suppression of key pro-inflammatory mediators at the cellular level.
- **Antidiabetic Potential**: Ethanolic extracts administered at 100–300 mg/kg produced time- and dose-dependent reductions in blood glucose in alloxan-induced diabetic rodent models, supported by in vitro α-glucosidase inhibition at an IC50 of 40.27 μg/mL.
- **Anticancer Activity**: In vitro cytotoxicity against MCF-7 human breast cancer cells was observed across multiple solvent extracts with IC50 values ranging from 48.117 to 115.218 μg/mL; mouse models showed reduced oral squamous cell carcinoma incidence with downregulation of cyclin D1, Ki-67, Bcl-2, and Cox-2.
- **Antimicrobial and Antifungal Effects**: Polyphenol-rich ethyl acetate extracts exhibit antifungal activity, consistent with the resin's traditional application as a topical antimicrobial agent for infected wounds and skin lesions.
- **Gastrointestinal Protection**: Traditional and some preclinical evidence supports antidiarrheal and antiulcer effects, attributed to tannin-mediated mucosal protection and antimicrobial action against enteric pathogens.

How It Works

The resin's flavonoids and homoisoflavonoids neutralize reactive oxygen species through direct hydrogen atom donation, with the homoisoflavonoid 7,8-methylenedioxy-3(4-hydroxybenzyl)chromane demonstrating free radical scavenging potency comparable to quercetin. Anti-inflammatory effects are mediated by suppression of the NF-κB pathway downstream of LPS stimulation, reducing macrophage production of nitric oxide, TNF-α, and IL-6 in RAW 264.7 cell models. Anticancer activity involves modulation of cell cycle progression and apoptosis, specifically downregulating cyclin D1, Ki-67 (proliferation marker), Bcl-2 (anti-apoptotic), p53, Cox-2, and EGFR while upregulating pro-apoptotic Bax and caspase-3 in oral squamous cell carcinoma models. The antidiabetic mechanism involves competitive or non-competitive inhibition of α-glucosidase, an intestinal enzyme critical for carbohydrate digestion, thereby blunting postprandial glucose excursions.

Scientific Research

Available evidence for Dracaena cinnabari is limited to in vitro cell culture studies and small, incompletely reported rodent experiments, with no human clinical trials published as of the available literature. In vitro studies have quantified cytotoxicity against MCF-7 cells (IC50 48–115 μg/mL depending on solvent extract) and α-glucosidase inhibition (IC50 40.27 μg/mL), providing mechanistic leads but no translational human data. Animal studies using alloxan-induced diabetic models and a 4-nitroquinoline-1-oxide-induced oral carcinoma model in mice demonstrated biological activity at 100–1000 mg/kg, but sample sizes, statistical power, and blinding procedures were not specified in available reports, substantially limiting interpretive confidence. The overall body of evidence is preliminary and exploratory; independent replication, pharmacokinetic characterization, and controlled human trials are entirely absent.

Clinical Summary

No human clinical trials investigating Dracaena cinnabari resin for any health indication have been conducted or reported in the accessible scientific literature. Preclinical rodent data suggest antidiabetic effects (blood glucose reduction at 100–300 mg/kg ethanolic extract) and anticancer activity (reduced tumor incidence and protein expression at 1000 mg/kg methanol extract in a mouse carcinoma model), but these studies lack reported sample sizes, control group details, and statistical rigor. In vitro cytotoxicity IC50 values of 48–115 μg/mL against MCF-7 cells are biologically interesting but cannot be extrapolated to human therapeutic doses without pharmacokinetic and bioavailability data. Confidence in clinical efficacy for any specific indication is very low; all observed benefits remain unproven in humans.

Nutritional Profile

Dracaena cinnabari resin is not a dietary food and provides no meaningful macronutrient or micronutrient content in typical use quantities. Its bioactive phytochemical profile includes flavanoids (7-hydroxy-3-(3-hydroxy-4-methoxybenzyl)chroman, 7-hydroxy-3-(4-hydroxybenzyl)-8-methoxychroman, 7,4′-dihydroxy-3′-methoxyflavan), chalcones (2′,4,4′-trihydroxychalcone), homoisoflavonoids (4′-hydroxy-7,8-methylenedioxyhomoisoflavan, 7,8-methylenedioxy-3(4-hydroxybenzyl)chromane), and the anthocyanin-like pigment dracorhodin. Additional constituents include sterols (cholesterol, lupeol, campesterol), terpenoids, condensed and hydrolyzable tannins, phenolic acids (notably gallic acid), and saponins. Specific concentrations of individual compounds within the intact resin are not routinely quantified in published literature; bioavailability of constituent polyphenols in humans is entirely unstudied, and solvent polarity significantly affects extraction yield and compound profile.

Preparation & Dosage

- **Traditional Resin (Topical)**: Crude red resin exudate applied directly to wounds or skin lesions for hemostatic and antimicrobial effects; no standardized preparation or dosing protocol established.
- **Traditional Resin (Oral)**: Resin dissolved or powdered and ingested for antidiarrheal and antiulcer purposes in Yemeni and Ayurvedic traditions; no human dose range quantified.
- **Methanolic Extract (Preclinical, Anticancer)**: 100–1000 mg/kg administered orally in rodent models; the 1000 mg/kg dose showed tumor protein suppression in oral carcinoma models.
- **Ethanolic Extract (Preclinical, Antidiabetic)**: 100–300 mg/kg in alloxan-induced diabetic rodents produced dose-dependent blood glucose reduction.
- **Safety Threshold (Animal)**: Methanol extract tolerated at up to 1500 mg/kg/day for 28 days in rats with no observed toxic effects; human equivalent dosing cannot be reliably extrapolated.
- **Standardization**: No commercial standardized extract, capsule, or tablet form has been established; no consensus on active marker compound for standardization exists.
- **Timing**: No human pharmacokinetic data available to guide dosing timing or frequency.

Synergy & Pairings

In traditional Yemeni ethnomedicine, dragon's blood resin is frequently combined with honey, which may provide complementary antimicrobial and wound-healing activity through distinct mechanisms including hydrogen peroxide generation and osmotic effects. The polyphenol-rich ethyl acetate fraction has demonstrated synergistic antioxidant activity in vitro when combined with other plant phenolic sources, suggesting potential combinatorial benefit with quercetin or gallic acid-rich botanicals such as pomegranate. No formal pharmacological synergy studies or standardized supplement stacks involving Dracaena cinnabari have been evaluated in controlled research settings.

Safety & Interactions

Preclinical acute and subchronic toxicity data are reassuring within animal models: methanolic resin extract was tolerated at 1500 mg/kg/day for 28 days in rats with no reported adverse effects, hematological abnormalities, or organ toxicity. No human adverse event data, drug interaction studies, or contraindication profiles exist, as no controlled human exposures have been formally reported in the scientific literature. Given the complete absence of human pharmacokinetic data, potential interactions with anticoagulants (due to hemostatic tannins), antidiabetic medications (due to α-glucosidase inhibitory activity), or cytochrome P450-metabolized drugs cannot be excluded and should be considered speculative risks. Use during pregnancy and lactation is unsupported by any safety data and should be avoided; a standardized maximum safe human dose has not been established.